A recent study on adoptive T-cell therapy (ACT) has suggested that PIM inhibition could be used alongside anti-PD1 (programmed death receptor 1) therapy.139 The cells obtained from PIM knock-out mice had lower glycolytic activity, S6 phosphorylation, interferon gamma secretion, and ROS levels than those from wild-type mice, which translates to decreased T-cell death, an increased memory phenotype, and superior tumor control and mouse survival. The gene discussed is PIM1; the disease is neoplasm.